Borosil Scientific Limited has informed the Exchange about seeking the approval of the shareholders by way of an enabling resolution at the ensuing Annual General Meeting, authorising the Board to raise funds, as and when required, up to an amount of Rs. 250 crores.
BOROSCI · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Borosil Scientific's board, at its May 21, 2025 meeting, approved seeking shareholder approval at the upcoming AGM to raise up to Rs. 250 crores through modes including QIP, further public offer, FCCBs, or other permissible methods. The board also approved audited financial results for Q4 and FY25 with an unmodified auditor opinion. On a standalone basis, FY25 revenue rose to Rs. 392.5 crore (vs Rs. 356.5 crore in FY24), with profit after tax at Rs. 35.0 crore (vs Rs. 31.5 crore), giving EPS of Rs. 3.94. Q4FY25 revenue grew to Rs. 117.7 crore (vs Rs. 102.9 crore in Q4FY24), with PAT of Rs. 14.2 crore. The Scientific segment (lab glass, equipment, process systems) drove profits, while the Glassware segment remained in loss. The company also introduced a VRS at its Nashik plant with financial impact to be recognised later.
The enabling fundraise resolution of Rs. 250 crore could lead to equity dilution if executed via QIP or FPO, though the mode and pricing are yet to be decided. Strong revenue and profit growth in FY25 along with healthy EPS improvement are positive signals for shareholders, while the Glassware segment losses and pending VRS cost recognition are mild watch points.